Paper98109
In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.
Yoshikawa TT and 1 other. Antimicrob Agents Chemother, 1978. Cited by 17 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa. Papers, record 98109. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/98109
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amikacin | Major topic |
| Kanamycin | Major topic |
| Penicillins | Major topic |
| Pseudomonas aeruginosa | Major topic |
| Ticarcillin | Major topic |
| Drug Interactions | |
| Microbial Sensitivity Tests |
Source PubMed
References11
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1,096,809 | Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. | Antimicrob Agents Chemother | 1975 | https://conductscience.org/library/papers/1096809 | PubMed |
| 2 | 1,190,752 | Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. | Antimicrob Agents Chemother | 1975 | https://conductscience.org/library/papers/1190752 | PubMed |
| 3 | 335,967 | Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients. | Antimicrob Agents Chemother | 1977 | https://conductscience.org/library/papers/335967 | PubMed |
| 4 | 406,837 | Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. | Antimicrob Agents Chemother | 1977 | https://conductscience.org/library/papers/406837 | PubMed |
| 5 | 4,157,342 | Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1974 | https://conductscience.org/library/papers/4157342 | PubMed |
| 6 | 4,201,634 | Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. | Ann Intern Med | 1973 | https://conductscience.org/library/papers/4201634 | PubMed |
| 7 | 4,994,878 | Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. | N Engl J Med | 1971 | https://conductscience.org/library/papers/4994878 | PubMed |
| 8 | 586,099 | Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. | Am J Med | 1977 | https://conductscience.org/library/papers/586099 | PubMed |
| 9 | 806,263 | BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1975 | https://conductscience.org/library/papers/806263 | PubMed |
| 10 | 816,250 | Emergence of gentamicin- and carbenicillin-resistant Pseudomonas aeruginosa in a hospital environment. | Antimicrob Agents Chemother | 1976 | https://conductscience.org/library/papers/816250 | PubMed |
| 11 | 825,022 | Synergism of cefazolin-gentamicin against enterococci. | Antimicrob Agents Chemother | 1976 | https://conductscience.org/library/papers/825022 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 26,031,965 | Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. | Curr Infect Dis Rep | 2015 | https://conductscience.org/library/papers/26031965 | PubMed |
| 24,184,742 | An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. | Virulence | 2014 | https://conductscience.org/library/papers/24184742 | PubMed |
| 22,763,634 | Combination therapy for treatment of infections with gram-negative bacteria. | Clin Microbiol Rev | 2012 | https://conductscience.org/library/papers/22763634 | PubMed |
| 7,002,527 | Ticarcillin: a review of its pharmacological properties and therapeutic efficacy. | Drugs | 1980 | https://conductscience.org/library/papers/7002527 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/98109
GET https://conductscience.org/api/papers/v1/98109/authors